Skip to main content

Written question asked by Baroness Tonge (Liberal Democrat) on Monday, 22 March 2004, in the House of Commons. It was due for an answer on Tuesday, 4 May 2004. It was answered by Melanie Johnson (Labour) on Tuesday, 4 May 2004 on behalf of the Department of Health.


Dept of Health

Question
To ask the Secretary of State for Health, what assessment he has made of the link between Thimerosal in vaccines and autism.
Answer

Dr. Tonge: To ask the Secretary of State for Health what assessment he has made of the link between Thimerosal in vaccines and autism. [163554] Miss Melanie Johnson: As with all medicinal products, vaccine safety is continually monitored by the Medicines and Healthcare products Regulatory Agency (MHRA) and its independent expert advisory body, the Committee on Safety of Medicines (CSM). The only vaccines currently used in the routine childhood immunisation programme that contain thiomersal (also known as thimerosal) are the combined diphtheria/tetanus/wholecell pertussis/Haemophilus influenzae type B and the diphtheria/tetanus vaccines. Measles/mumps/rubella (MMR) vaccine does not contain thiomersal. The MHRA and CSM have thoroughly reviewed the safety of thiomersal-containing vaccines, including alleged links with autism, on a number of occasions. In 2001, CSM conducted a major review of the available evidence and has considered new data as it has emerged. Following a review of further studies in 2003, including two United Kingdom studies involving more than 100,000 children, CSM advice was placed on the MHRA website at http://medicines.mhra.gov.uk. Further studies from Denmark involving almost half a million children have also specifically investigated the suggested link between thiomersal-containing vaccines and autism. None of these studies found any evidence of a causal association. On the basis of the available data, the advice of CSM remains that there is no evidence of harm from thiomersal contained in vaccines, with the exception of possible hypersensitivity reactions (typically skin rashes or local swelling at the site of injection). The CSM advises that the benefits of immunisation with such vaccines outweigh any potential risks of vaccination. This view concurs with that of the World Health Organisation.


Secondary information

Type
Written question
Reference
420 c1474-5W; 163554
Session
2003-04
Subjects
Autism Vaccination Side effects Thiomersal
Link
View this Written question on www.publications.parliament.uk